Purpose. To evaluate perioperative blood loss and blood transfusion requirement in patients who underwent dynamic hip screw plate fixation for a stable trochanteric fracture with or without preoperative intravenous tranexamic acid (TXA). Methods. 49 men and 11 women (mean age, 56.5 years) who underwent open reduction and internal fixation with a dynamic hip screw plate for a stable trochanteric fracture by a single surgeon were equally randomised to receive either a single dose of intravenous TXA (15 mg/kg) 15 minutes prior to surgery or an equal volume of normal saline by slow infusion. Intra-and post-operative blood loss and the need for blood transfusion were assessed, as was any thromboembolic adverse event. Results. The TXA and control groups were comparable in terms of age, gender, body mass index, blood pressure, pulse rate, time from injury to surgery, operating time, and preoperative haematological data. Blood loss was lower in the TXA
than control group intraoperatively (320.3 vs. 403.33 ml, p<0.001), during 0 to 24 hours (61.67 vs. 186.67 ml, p<0.001), and during 24 to 48 hours (27 vs. 86.67 ml, p<0.001), as well as the total volume (408.97 vs. 676.67 ml, p<0.001). Respectively for the TXA and control groups, 27 and 30 required 28 and 41 units of blood intra-operatively (p<0.001), and 6 and 15 required 6 and 15 units of blood postoperatively (p=0.014). No patient had any thromboembolic adverse event. Conclusion. TXA is safe and effective in reducing blood loss in dynamic hip screw plate fixation for stable trochanteric fractures.
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Internal fixation for trochanteric fractures entails considerable blood loss. Perioperative administration of tranexamic acid (TXA) stabilises multiple microclots within the surgical wound and reduces blood loss. 1 TXA is a synthetic amino acid 2 that acts as an antifibrinolytic agent to competitively block the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator, thereby retarding fibrinolysis and blood clot degradation. 3 This study evaluated perioperative blood loss and blood transfusion requirement in patients who underwent dynamic hip screw plate fixation for a stable trochanteric fracture with or without preoperative intravenous TXA.
Materials and Methods
This study was in accordance with the Declaration of Helsinki and approved by the ethics committee of our hospital. Written informed consent was obtained from each patient. In 10 consecutive patients who had undergone trochanteric fracture surgery, the mean perioperative blood loss was 710 ml. Based on a clinically relevant blood loss of 210 ml (30%) and a standard deviation of 260 ml, a sample of 27 subjects per group was needed to achieve 90% power at a 5% level of significance (2-sided tests). To accommodate a maximum drop-out rate of 10%, 30 subjects per group were recruited. 49 men and 11 women (mean age, 56.5 years) who underwent open reduction and internal fixation with a dynamic hip screw plate for a stable trochanteric fracture (AO 31A1 and 31A2.1 types) by a single surgeon between October 2013 and April 2015 were equally randomised to receive either a single dose of intravenous TXA (15 mg/kg) 15 minutes prior to surgery or an equal volume of normal saline (0.9% NaCl) by slow infusion.
Patients were excluded who had (1) a fracture unsuitable for dynamic hip screw plate fixation, (2) an allergy to TXA, (3) preoperative renal impairment (serum creatinine >2 mg% or creatinine clearance <30 ml/min), (4) preoperative hepatic impairment (international normalised ratio [INR] for prothrombin time >1.5 or liver enzymes elevated by >3 times the normal range, (5) known bleeding disorder or preoperative coagulation anomaly determined by prolonged bleeding time and clotting time, an INR >1.5, or a prolonged partial thromboplastin time, (6) a history of any thrombo-embolic events (such as cerebrovascular accident, acute coronary syndrome/ myocardial infarction, pulmonary embolism, deep vein thrombosis, or arterial thrombosis), (7) anticoagulants or aspirin-like drugs, oestroprogestive drugs, or long-acting non-steroidal anti-inflammatory drugs, or (8) were pregnant or breastfeeding.
Surgical procedure was standardised. Under spinal anaesthesia, a 10 cm incision was made, and the vastus lateralis was exposed through an L-shaped incision. Diathermy was routinely used. Intraoperative blood loss was measured by weighing used gauze pieces and mops. The weight (g) was then converted to volume (ml). Blood collected in the suction bottle was measured by subtracting the volume of saline used for wash. A low-vacuum drain was inserted in the sub-muscular plane. Postoperative blood loss in the drain collector was measured at 24 and 48 hours. Haemoglobin and haematocrit levels were measured at 48 hours. The indication for blood transfusion was set at haemoglobin level <8.5 g/dl or haematocrit level <27%.
Patients were assessed for deep vein thrombosis (based on the Homan sign and Mose sign and confirmed by compression ultrasonography upon clinical suspicion), pulmonary embolism (confirmed by spiral computed tomography), cerebrovascular accident (confirmed by computed tomographic scan or magnetic resonance imaging), and acute coronary syndrome or myocardial infarction (confirmed by troponin I estimation and ECG changes)
Normality of distribution of data was confirmed using the Kolmogorov-Smirnov test with Lilliefors correction. The TXA and control groups were compared using unpaired (2 tailed) t-test for continuous variables and the Fisher's exact test for qualitative variables. A p value of <0.05 was considered statistically significant.
results
The TXA and control groups were comparable in terms of age, gender, body mass index, blood pressure, pulse rate, time from injury to surgery, operating time, and preoperative haematological data (Table) . Blood loss was lower in the TXA than control group intraoperatively (320.3 vs. 403.33 ml, p<0.001), during 0 to 24 hours (61.67 vs. 186.67 ml, p<0.001), and during 24 to 48 hours (27 vs. 86.67 ml, p<0.001), as well as the total volume (408.97 vs. 676.67 ml, p<0.001). The TXA group had higher haemoglobin (9.65 vs. 8.92 g/dl, p=0.039) and haematocrit (32.29% vs. 30.58%, p=0.002) levels at 48 hours (Table) .
Respectively for the TXA and control groups, 27 and 30 required 28 and 41 units of blood intraoperatively (p<0.001), and 6 and 15 required 6 and 15 units of blood postoperatively (p=0.014) [Table] .
No patient had any thromboembolic adverse event such as deep vein thrombosis, cerebrovascular accident, pulmonary embolism, acute coronary syndrome, or myocardial infarction.
discussion
Blood-sparing strategies include preoperative autologous blood donation, acute normovolaemic haemodilution, pharmacological therapies, increased red blood cell production by use of erythropoietin, reduced bleeding by use of antifibrinolytics or topical haemostatic agents, use of recombinant factor VII, and improved surgical and anaesthetic techniques. 4 Use of TXA is relatively inexpensive and has few side effects. 3, 5, 6 TXA is the trans-stereoisomer of 4-aminoethylcyclohexane carbolic acid and has a half life of 80 minutes. It is 3% protein bound and 95% is excreted unchanged in the kidneys. 2 There is no consensus on the optimal dose of TXA. It has been established that a therapeutic plasma concentration of TXA of 10 ng ml -1 is required for an 80% reduction in the activity of plasminogen activator to suppress fibrinolysis in tissues. An intravenous dose of TXA 10 mg/kg can maintain such plasma concentration for only 3 hours. This may be insufficient to prevent postoperative bleeding and thus higher doses have been suggested. 7 In patients with total hip replacement, reduction in postoperative blood loss is similar when TXA is given at the end of surgery or 3 hours later. 8 A preoperative intravenous dose of TXA 15 mg/kg has been reported to reduce postoperative and total blood loss and units of packed cells required in primary total hip replacement surgery. 9 In contrast to elective hip or knee replacement surgery, trochanteric fractures activate and increase the fibrinolytic system during surgery. Thus, TXA should be given 15 minutes prior to skin incision to ensure that the clot stabilising effect can cover both intra-and post-operative periods.
A single intravenous dose of TXA 15 mg/kg at induction of anaesthesia has been reported to significantly reduce bleeding in hip fracture patients: intra-operative blood loss of 652±228 vs. 1108±372 ml, 10 or 630±220 vs. 850±260 ml, 11 and postoperative blood loss of 296±85 vs. 375±110 ml, 10 or 520±280 vs. 920±410 ml. 11 In addition, in total hip or knee replacement, TXA has been reported to effectively decrease blood loss [7] [8] [9] 12, 13 and allogeneic blood transfusion requirement (0.80 vs. 3.17 units) 12 as well as the percentage of patients requiring blood transfusion (52% vs. 100%, 12 
